Gilead (GILD) Stock May Be 44% Undervalued After Lenacapavir News

Gilead Sciences has seen a powerful rerating in recent years, so the live question for investors is whether the current share price lines up with the cash the business is expected to generate. With the stock now reflecting years of optimism about its HIV, liver disease and cell therapy franchises, the focus naturally shifts to what the underlying cash flows can support.

• Over the past 5 years, Gilead Sciences has delivered a 196.0% share price return, which puts a lot of weight on whether the cash flow outlook can keep justifying that kind of compounding.
• Recent positive trial data for lenacapavir and Livdelzi, along with progress in CAR T therapies, can influence expectations for future cash generation by affecting how durable and diversified Gilead Sciences' treatment portfolio may become.
• What if you looked at Gilead Sciences through its sales instead? See what Gilead Sciences's 6.7x P/S says about the price.

The issue now is whether that recent share price level is appropriately supported by Gilead Sciences' projected cash flows when valued using a Discounted Cash Flow (DCF) approach.

If you want to test the same cash flow question you are asking of Gilead Sciences across a wider set of biopharma opportunities, run those checks through 32 high quality undervalued stocks

Does Gilead Sciences Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) approach here takes Gilead Sciences' current free cash flow and projects it in two stages before discounting it back to today. On the latest twelve month view, the group is generating about $13.8b of free cash flow, so even modest percentage moves in either direction can matter a lot for what the equity is worth.

The model assumes free cash flow keeps growing from this base, with projected annual figures rising into the $16b to $21b range over the next decade. That profile looks more like a mature but expanding cash engine than an early stage swing factor story, which helps explain why the output of the DCF sits substantially above the current share price of $167.95. Because the PURPOSE 5 trial for lenacapavir and the strong Q3 2026 update both speak to support for the HIV franchise, the market reaction so far still leaves the stock trading below what this cash flow stream suggests. Find out what Gilead Sciences could be worth using our Discounted Cash Flow (DCF) estimate.

The Gilead Sciences Narrative: What Would Justify Today's Price?

Narratives pick up where the DCF puzzle leaves off for Gilead Sciences, by spelling out which paths for revenue growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price on Simply Wall St's Community page. Rather than a single output from a model or ratio, each narrative lays out the assumptions that sit behind its view of fair value so you can see how those expectations compare with future results.

Gilead Sciences divides opinion between a long-lived HIV and oncology cash engine and a pricier, execution-heavy expansion story.

Bull case: 16% undervalued

According to the bullish analyst Narrative on Simply Wall St, the opportunity hinges on how far lenacapavir and oncology can reshape Gilead Sciences.

"The growing suite of long-acting HIV treatment options built around lenacapavir, including weekly and monthly oral combinations and injectable regimens with multi month coverage, creates room for Gilead Sciences to shift more of its HIV portfolio toward formats that can support a higher value mix…"

Discover why this Narrative puts Gilead Sciences at 16% undervalued.

Bear case: 31% overvalued

According to kapirey, an investor in the Simply Wall St Community, the concern is whether Gilead Sciences can justify richer expectations through clean execution.

"Bear case: Execution risk (M&A integration, oncology competition, pricing pressure) and near-term EPS dilution…"

Explore why this Narrative puts Gilead Sciences at 31% overvalued.

One more angle on Gilead Sciences that can move the needle

Cash flow models say a lot about Gilead Sciences, but the people steering that cash engine and how their rewards line up with your interests could tell you even more. See who runs Gilead Sciences and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com